PT-141 10mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH) and a metabolite of Melanotan II. PT-141 has been studied primarily for its agonist activity at melanocortin 3 and 4 receptors (MC3R and MC4R), which are implicated in the central regulation of sexual behavior. It has become a significant research compound for investigating melanocortin-mediated neurobehavioral pathways in preclinical models.

PT-141 (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) shares the cyclic heptapeptide scaffold of Melanotan II but is studied as a distinct compound due to its pharmacokinetic profile and receptor engagement focus. Its selective activity at MC3R and MC4R, without significant MC1R engagement, makes it a useful tool for isolating central melanocortin effects from peripheral pigmentation pathways. Supplied as 10mg lyophilized peptide for in vitro and preclinical research applications.

For research purposes only. Not for human or animal consumption. Store lyophilized peptide at -20°C. Protect from light and moisture. Reconstituted solutions should be handled promptly or stored at -20°C for short-term research applications only.

PT-141 acts primarily on melanocortin 3 and 4 receptors (MC3R and MC4R), which are implicated in central melanocortin signaling. Unlike PDE5 inhibitors, its mechanism operates through melanocortin signaling rather than vascular pathways. Clinical research has investigated PT-141 in Phase II and Phase III trials, and a formulation has received FDA approval for a specific indication, providing a body of published clinical data.